Rodent models of cardiopulmonary disease: Their potential applicability in studies of air pollutant susceptibility

Environmental Health Perspectives

Volumn 106, Issue SUPPL. 1, 1998, Pages 111-130

  Kodavanti, Urmila R ^a   Costa, Daniel L ^a   Bromberg, Philip A ^b  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Ambient air particulate matter; Cardiac disease models; Cardiopulmonary disease models; Pulmonary disease models; Pulmonary infection models; Rodent models; Susceptibility

Indexed keywords

AIR POLLUTANT; AIR POLLUTION; ALLERGY; ANIMAL MODEL; ASTHMA; BRONCHITIS; CARDIOPULMONARY HEMODYNAMICS; CARDIOPULMONARY INSUFFICIENCY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; DISEASE MODEL; DISEASE PREDISPOSITION; EMPHYSEMA; FIBROSING ALVEOLITIS; GENETICS; HYPERTENSION; INFECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0031977575     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.98106s1111     Document Type: Review

References (315)

1. Brain JD, Valberg PA, Mensah GA. Species differences. In: Variations in Susceptibility to Inhaled Pollutants. Identification, Mechanisms, and Policy Implications (Brain JD, Beck BD, Warren AJ, Shaikh RA, eds). Baltimore:The Johns Hopkins University Press, 1988;89-103.
2. Sweeney TD, Brain JD, Godleski JJ. Preexisting disease. In: Variations in Susceptibility to Inhaled Pollutants. Identification, Mechanisms, and Policy Implications (Brain JD, Beck BD, Warren AJ, Shaikh RA, eds). Baltimore:The Johns Hopkins University Press, 1988;142-158.
3. Kacew S, Ruben Z, McConnell RF. Strain as a determinant factor in the differential responsiveness of rats to chemicals. Toxicol Pathol 23:701-714 (1995).
4. Kodavanti UP, Jaskot RH, Su W-Y, Costa DL, Ghio AJ, Dreher KL. Genetic variability in combustion particle-induced chronic lung injury. Am J Physiol 272 (Lung Cell Mol Physiol 16):L521-L532 (1997).
5. Pope CA III, Dockery DW, Schwartz J. Review of epidemiological evidence of health effects of particulate air pollution. Inhal Toxicol 7:1-18 (1995).
6. Dockery DW, Pope CA III, Xu X, Spengler JD, Ware JH, Fay ME, Ferris BG, Speizer FE. An association between air pollution and mortality in six U.S. cities. N Engl J Med 329:1753-1759 (1993).
7. Schwartz J. What are people dying of on high air pollution days? Environ Res 64:26-35 (1994).
8. Schwartz J. Air pollution and daily mortality: a review and meta analysis. Environ Res 64:36-52 (1994).
9. Schwartz J, Morris R. Air pollution and hospital admissions for cardiovascular disease in Detroit, Michigan. Am J Epidemiol 142:23-35 (1995).
10. Burnett RT, Dales R, Krewski D, Vincent R, Dann T, Brook JR. Associations between ambient particulate sulfate and admissions to Ontario hospitals for cardiac and respiratory diseases. Am J Epidemiol 142:15-22 (1995).
11. Dockery DW, Schwartz J. Particulate air pollution and mortality: more than the Philadelphia story. Epidemiology 6:629-632 (1995).
12. Roemer W, Hoek G, Brunckreef B. Effect of ambient winter air pollution on respiratory health of children with chronic respiratory symptoms. Am Rev Respir Dis 147:118-124 (1993).
13. 10 particulates: are they the major determinants of pediatric respiratory admissions in Utah County, Utah (1985-1989). Ann Occup Hyg38 (Suppl 1):969-972 (1994).
14. Neas L, Dockery DW, Koutrakis P, Tollerud DJ, Speizer FE. The association of ambient air pollution with twice daily peak expiratory flow rate measurements in children. Am J Epidemiol 141:111-122 (1995).
15. McClellan RO, Millar FJ. An overview of EPA's proposed revision of the particulate matter standard. CIIT Activities 17:1-22 (1997).
16. Samet JM, Zeger SL, Berhane K. The association of mortality and particulate air pollution. In: Particulate Air Pollution and Daily Mortality. Replication and Validation of Selected Studies. Phase 1. Report of the Particle Epidemiology Evaluation Project. Cambridge, MA:Health Effects Institute, 1995;3-103.
17. Selgrade MJK, Gilmour MI. Effects of gaseous air pollutants on immune responses and susceptibility to infectious and allergic disease. In: Immunotoxicology and Immunopharmacology (Dean JH, Luster MI, Munson AE, Kimber I, eds). New York:Raven Press, 1994;395-411.
18. Gilmour MI. Interaction of air pollutants and pulmonary allergic responses in experimental animals. Toxicology 105:335-342 (1995).
19. Hartroft PM, Kuhn III CC, Freeman SV, Tansuvan C, Gregory RO, Gardner RA. Effects of chronic, continuous exposure to simulated urban air pollution on laboratory animals with cardiovascular and respiratory diseases. No 75CH1004-134-5. Piscataway, NJ:The Institute of Electrical and Electronics Engineers, Inc., USA 1976;1-5.
20. Drew RT, Kutzman RS, Costa DL, Iwai J. Effects of sulfur dioxide and ozone on hypertension sensitive and resistant rats. Fundam Appl Toxicol 3:298-302 (1983).
21. Shiotsuka RN, Drew RT, Wehner RW. Carbon monoxide enhances development of hypertension in Dahl rats. Toxicol Appl Pharmacol 76:225-233 (1984).
22. Kurzman RS, Wehner RW, Haber SB. Selected responses of hypertension-sensitive and resistant rats to inhaled acrolein. toxicology 31:53-65 (1984).
23. Kutzman RS, Wehner RW, Haber SB. The impact of inhaled acrolein on hypertension-sensitive and resistant rats. J Environ Pathol Toxicol Oncol 6:97-108 (1986).
24. Costa DL, Lehmann JR, Frazier LT, Doerfler D, Ghio A. Pulmonary hypertension: a possible risk factor in paniculate toxicity [Abstract]. Am J Respir Crit Care Med 149:A480 (1994).
25. Kodavanti UP, Costa DL, Jaskot R, Richards JH, Dreher KL. Influence of preexisting pulmonary disease on residual oil fly ash particle-induced toxicity in the rat [Abstract]. Am J Respir Crit Care Med 153:A542 (1996).
26. Kodavanti UP, Jackson M, Gardner SY, Watkinson WP, Campen MJ, Richards J, Costa DL. Particle-induced lung injury in hypertensive rats [Abstract]. Am Rev Respir Crit Care Med 155:A247 (1997).
27. Killingsworth CR, Alessandrini F, Krishna Murthy GG, Catalano PJ, Paulauskis JD, Godleski JJ. Inflammation, chemokine expression, and death in monocrotaline-treated rats following fuel oil fly ash inhalation. Inhal Toxicol 9:541-565 (1997).
28. Watkinson WP, Campen MJ, Costa DL. Cardiac arrhythmia induction after exposure to residual oil fly ash particles in a rat model of pulmonary hypertension. Toxicol Sci (in press).
29. Seacon A, Godden DJ, Brown K. Increase in asthma: a more toxic environment or a more susceptible population? Thorax 49:171-174 (1994).
30. Peters A, Doring A, Wichmann H-E, Kroenig W. Increased plasma viscosity during an air pollution episode: a link to mortality? Lancet 349:1582-1587 (1997).
31. Classer SW, Korfhagen TR, Wert SE, Whitsert JA. Transgenic models for study of pulmonary development and disease. Am J Physiol 267 (Lung Cell Mol Physiol 11):L489-L497 (1994).
32. Stripp BR, Whitsett JA, Larder DL. Strategies for analysis of gene expression: pulmonary surfactant proteins. Am J Physiol 259:L185-L197 (1990).
33. Ho YS. Transgenic models for the study of lung biology and disease. Am J Physiol 266:L319-L353 (1994).
34. Slauson DO, Hahn FF. Criteria for development of animal models of diseases of the respiratory system. Am J Pathol 101:103-122 (1980).
35. Reid LM. Needs for animal models of human diseases of the respiratory system. Am J Pathol 101:589-5101 (1980).
36. King A, Smith P, Heath D. Ultrastructural difference between pulmonary arteriolar muscularization induced by hypoxia and monocrotaline. Exp Mol Pathol 61:24-35 (1994).
37. Heath D. The rat is a poor model for the study of human pulmonary hypertension. Cardioscience 3:1-6 (1992).
38. Cugell DW. COPD: a brief introduction for behavioral scientists. In: Chronic Obstructive Pulmonary Disease. A Behavioral Perspective (McSweeny AJ, Grant I, eds). New York:Marcel Dekker, 1988;1-18.
39. Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 154:959-967 (1996).
40. Dehaller R, Reid L. Adult chronic bronchitis: morphology, histochemistry, and vascularization of the bronchial mucus glands. Med Thorac 22:549-567 (1965).
41. Robbins SL, Cotran RS, Kumar S, eds. The respiratory system- lung. In: Pathologic Basis of Disease. Philadelphia:WB Saunders, 1984;725-726.
42. Jany B, Basbaum C. Mucin in disease. Modification of mucin gene expression in airway disease. Am Rev Respir Dis 144:S38-S41 (1991).
43. Chakrin LW, Saunders LZ. Experimental chronic bronchitis. Pathology in the dog. Lab Invest 30:145-154 (1974).
44. Drazen JM, O'Cain CF, Ingram RH Jr. Experimental Induction of chronic bronchitis in dogs. Effects on airway obstruction and responsiveness. Am Rev Respir Dis 126:75-79 (1982).
45. 2- induced bronchitis in dogs. Am Rev Respir Dis 129:790-797 (1984).
46. Shore S, Kariya ST, Anderson K, Skornik W, Feldman HA, Penington J, Godleski J, Drazen JM. Sulfur-dioxide-induced bronchitis in dogs. Effects on airway responsiveness to inhaled and intravenously administered methacholine. Am Rev Respir Dis 135:840-847 (1987).
47. Shore S, Kobzik L, Long NC, Skornik W, van Staden CJ, Boulet L, Rodger IW, Pon DJ. Increased airway responsiveness to inhaled methacholine in a rat model of chronic bronchitis. Am J Respir Crit Care Med 151:1931-1938 (1995).
48. Goldring IP, Cooper P, Ratner IM, Greenburg L. Pulmonary effects of sulfur dioxide exposure in the Syrian hamster. Combined with viral respiratory disease. Arch Environ Health 15:167-176 (1967).
49. Goldring IP, Greenburg L, Park S-S, Ratner IM. Pulmonary effects of sulfur dioxide exposure in the Syrian hamster. II: Combined with emphysema. Arch Environ Health 21:32-37 (1970).
50. Snider GL. Animal models of chronic airways injury. Chest 101(Suppl 3): 74S-79S (1992).
51. Farone A, Huang S, Paulauski J, Kobzik L. Airway neutrophilia and chemokine mRNA expression in sulfur dioxide-induced bronchitis. Am J Respir Cell Molec Biol 12:345-350 (1995).
52. Goco RV, Kress MB, Brantigan OC. Comparison of mucus glands in the tracheal bronchial tree of man and animals. Ann NY Acad Sci 106:555-571 (1963).
53. Jeffery PK. Morphologic features of airway surface epithelial cells and glands. Am Rev Respir Dis 128:S14-S20 (1983).
54. U.S. Department of Health, Education, and Welfare. Toxicological Effects of Sulfur Oxides on Animals. Publ No AP-50. Washington:Public Health Service, National Air Pollution Control Administration, 1969.
55. Costa DL, Kutzman RS, Lehmann JR, Drew RT. Altered lung function and structure in the rat after subchronic exposure to acrolein. Am Rev Respir Dis 133:286-291 (1986).
56. Harkema JR, Hotchkiss JA. In vivo effects of endotoxin on intraepithelial mucosubstances in rat pulmonary airways. Quantitative histochemistry. Am J Pathol 141:307-317 (1992).
57. Ogawa H, Fugimura M, Saito M, Matsuda T, Akao N, Kondo K. The effect of the neurokinin antagonist FK-224 on the cough response to inhaled capsaicin in a new model of guinea- pig eosinophilic bronchitis induced by intranasal polymyxin B. Clin Auton Res 4:19-27 (1994).
58. Sweeny TD, Skornik WA, Brain JD, Hatch V, Godleski JJ. Chronic bronchitis alters the pattern of aerosol deposition in the lung. Am J Respir Crit Care Med 151:482-488 (1995).
59. Godleski JJ, Sioutas C, Katler M, Catalano P, Koutrakis P. Death from inhalation of concentrated ambient air particles in animal models of pulmonary disease. In:Proceedings of the Second Colloquium on Pasticutate Air Polution and Human Health (Lee J, Phelan R, eds). 1-3 May 1996, University of Utah, Park City, Utah, 1996;4-136-4-143.
60. Snider GL, Lucey EC, Stone PJ. Animal models of emphysema. Am Rev Respir Dis 133:149-169 (1986).
61. Snider GL. Emphysema: the first two centuries and beyond. A historical overview, with suggestions for future research: part 2. Am Rev Respir Dis 146:1615-1622 (1992).
62. Surgeon General. The Health Consequences of Smoking: Chronic Obstructive Lung Disease. Washington:U.S. Government Printing Office, 1984.
63. Janoff A. Biochemical links between cigarette smoking and pulmonary emphysema. J Appl Physiol 55:285-293 (1983).
64. Eriksson S. Pulmonary emphysema and alpha 1-antitrypsin deficiency. Acta Med Scand 175:197-205 (1964).
65. Karlinsky JB, Snider GL. Animal model of emphysema. Am Rev Respir Dis 117:1109-1133 (1978).
66. Reichart E, Boerkmann P, Plenat F. Trypsin-triggerea emphysema: an established model in rats. Respir Med 88:701-702 (1994).
67. Deschamps C, Farkas GA, Beck KC, Schroeder MA, Hyatt RE. Experimental emphysema. Chest Surgery Clin N Am 5:691-699 (1995).
68. Snider GL, Hayes JA, Korthy AL, Lewis GP. Centrilobular emphysema experimentally induced by cadmium chloride aerosol. Am Rev Respir Dis 108:40-48 (1973).
69. Heckman CA, Dalbey WE. Pathogenests of lesions induced in rat lung by chronic tobacco smoke inhalation. J Natl Cancer Inst 69:117-129 (1982).
70. Niewoehner DE, Hoidal JR. Lung fibrosis and emphysema: divergent responses to a common injury? Science 217:359-360 (1982).
71. Riley DJ, Kerr JS, Yu SY, Berg RA, Edelman NH. Pulmonary oxygen toxicity. Connective tissue changes during injury and repair. Chest 83(Suppl):98-99 (1983).
72. Janoff A. Elastase and emphysema. Current assessment of the protease-antiprotease hypothesis. Am Rev Respir Dis 132:417-433 (1985).
73. Lucey EC, Stone PJ, Christensen TG, Breuer R, Snider GL. An 18-month study of the effects on hamster lungs of intratracheally administered human neutrophil elastase. Exp Lung Res 14:671-686 (1988).
74. Fonzi L, Lungarella G. Correlation between biochemical and morphological repair in rabbit lungs after elastase injury. Lung 158:165-171 (1980).
75. Valentine R, Rucker RB, Chrisp CE, Fihser GL. Morphological and biochemical features of elastase-induced emphysema in strain A/J mice. Toxicol Appl Pharmacol 68:451-461 (1983).
76. Busch RH, Lauhala KE, Loscutoff SM, McDonnald KE. Experimental pulmonary emphysema induced in the rat by intratracheally administered elastase: morphogenesis. Environ Res 33:497-513 (1984).
77. Diamond L, Kimmel EC, Lai Y-L, Winsett DW. Augmentation of elastase-induced emphysema by cigarette smoke. Effects of reduced nicotine content. Am Rev Respir Dis 138:1201-1206 (1988).
78. Kuhn C, Starcher B. The effect of lathyrogens on the evolution of elastase-induced emphysema. Am Rev Respir Dis 122:453-460 (1980).
79. Ranga V, Grahn D, Journey TM. Morphologic and phenotypic analysis of an outcross line of blotchy mouse. Exp Lung Res 4:269-279 (1983).
80. Szapiel SV, Fulmer JD, Hunninghake GW, Elson NA, Kawanami O, Ferrans VJ, Crystal RG. Hereditary emphysema in the tight-skin (Tsk/ +) mouse. Am Rev Respir Dis 123:680-685 (1981).
81. de Santi MM, Martorana PA, Cavarra E, Lungarella G. Pallid mice with genetic emphysema. Neutrophil elastase burden and elastin loss occur without alteration in the bronchoalveolar lavage cell population. Lab Invest 73:40-47 (1995).
82. Snider GL, Lucey EC, Paris B, Jung-Legg Y, Stone PJ, Franzblau C. Cadmium chloride-induced airspace enlargement with interstitial pulmonary fibrosis is not associated with destruction of lung elastin. Implications for the pathogenesis of human emphysema. Am Rev Respir Dis 137:918-923 (1988).
83. Glassgow JE, Pietra GG, Abrams WR, Blank J, Openheim DM, Weinbaum G. Neutrophil recruitment and degranulation during induction of emphysema in the rat by nitrogen dioxide. Am Rev Respir Dis 135:1129-1136 (1987).
84. Harkema JR, Mauderly JL, Gregory RE, Pickrell JA. A comparison of starvation and elastase models of emphysema in the rat, Am Rev Respir Dis 129:584-591 (1984).
85. Soskel NT, Watanabe S, Sandberg LB, Mechanisms of lung injury in the copper-deficient hamster model of emphysema. Chest 85(Suppl):70-73 (1984).
86. Raub JA, Miller FJ, Graham JA, Gardner DE, O'Neil JJ. Pulmonary function in normal and elastase treated hamsters exposed to a complex mixture of olefin-ozone-sulfur dioxide reaction products. Environ Res 31:302-310 (1983).
87. Costa DL, Lehmann JR. Emphysema and fibrosis: risk factors in responsiveness to air pollution. In: Proceedings of 15th Annual Conference on Environmental Toxicology, 30 October-1 November 1984, University of California, Irvine, California. AFAMRL-TR-84-002. Springfield, VA:National Technical Information Service, 1985;23-35.
88. Loscutoff SM, Cannon WC, Buschbom RL, Busch RH, Killand BW. Pulmonary function in elastase-treated guinea pigs and rats exposed to ammonium sulfate or ammonium nitrate aerosols. Environ Res 36:170-180 (1985).
89. 2 chronic exposure on elastase-induced emphysema. Environ Res 43:75-84 (1987).
90. Yokoyama E, Nambu Z, Ichikawa I, Uchiyama I, Arakawa H. Pulmonary response to exposure to ozone of emphysematous rats. Environ Res 42:114-120 (1987).
91. Smith LG, Busch RH, Buschbom RL, Cannon WC, Loscutoff SM, Morris JE. Effect of sulfur dioxide or ammonium sulfate exposure alone or combined, for 4 or 8 months on normal and elascase-impaired rats. Environ Res 49:60-78 (1989).
92. Harkema JR, Mauderly JL, Hahn FF. The effect of emphysema on oxygen toxicity in rats. Am Rev Respir Dis 126:1058-1065 (1982).
93. Mauderly JL, Bice DE, Cheng YS, Gillett NA, Henderson RF, Pickrell JA, Wolff RK. Influence of experimental pulmonary emphysema on the toxicological effects from inhaled nitrogen dioxide and diesel exhaust. Res Rep Health Eff Inst 30:1-47 (1989).
94. Mauderly JL, Bice DE, Cheng YS, Gillett NA, Griffith WC, Henderson RF, Pickrell JA, Wolff RK. Influence of preexisting pulmonary emphysema on susceptibility of rats to inhaled diesel exhaust. Am Rev Respir Dis 141:1333-1341 (1990).
95. Sweeney TD, Brain JD, Leavitt SA, Godleski JJ. Emphysema alters the deposition pattern of inhaled particles in hamsters. Am J Pathol 128:19-28 (1987).
96. Cookson WOCM, Moffatt MF. Asthma: an epidemic in the absence of infection? Science 275:41-42 (1997).
97. Hogg JC. The pathology of asthma. Clin Chest Med 5:567-571 (1984).
98. Johnston SL, Holgate ST. The inflammatory response in asthma. Br J Hosp Med 46:84-90 (1991).
99. Arm JP, Lee TH. Pathobiology of bronchial asthma. Adv Immunol 51:323-3382 (1992).
100. Buss WW, Calhoun WF, Sedgewick JD. Mechanism of airway inflammation in asthma. Am Rev Respir Dis 147:S20-S24 (1993).
101. Gilmour MI, Selgrade MJK. A model of immune-mediated lung disease in rats sensitized to house dust mite and upregulation of immunity following exposure to nitrogen dioxide [Abstract]. Chest 109(Suppl 3):69S (1996).
102. Rochester CL, Rankin JA. Is asthma T-cell mediated? Am Rev Respir Dis 144:1005-1007 (1991).
103. Frew AJ. The immunology of respiratory allergies. Toxicol Lett 86:65-72 (1996).
104. Roche WR, Beasley R, Williums JH, Holgate ST. Subepithelial fibrosis of bronchi of asthmatics. Lancet I:520-524 (1989).
105. Jeffery PK. Histologkal features of the airways in asthma and COPD. Respiration 59(Suppl I):13-16 (1992).
106. Wardlaw AJ, Dunnerre S, Gleich GJ, Collins JV, Kay AB. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. Am Rev Respir Dis 137:62-69 (1988).
107. Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 139:806-817 (1989).
108. Karole MH, Stadier J, Magreni C. Immunotoxicologic evaluation of the respiratory system: animal models for immediate- and delayed-onset pulmonary hypersensitivity. Fundam Appl Toxicol 5:459-472 (1985).
109. Elwood W, Lotvall JO, Barnes PJ, Chung KF. Characterization of allergen-induced bronchial hyperresponsiveness and airway inflammation in actively sensitized Brown-Norway rats. J Allergy Clin Immunol 88:951-960 (1991).
110. Tarayre JP, Alaga M, Barbara M, Tisseyre N, Vieu S, Tisne- Versailles J. Model of bronchial allergic inflammation in the Brown Norway rat. Pharmacological modulation. Int J Immunopharmacol 14:847-855 (1992).
111. Bittleman DB, Casale TB. Allergic models and cytokines. Am J Respir Crit Care Med 150:572-576 (1994).
112. Kung TT, Jones H, Adams III GK, Umland SP, Kreutner W, Egan RW, Chapman RW, Watnick AS. Characterization of a murine model of allergic pulmonary inflammation. Int Arch Allergy Immunol 105:83-90 (1994).
113. + lymphocytes in a LEW rat model of hypersensitivity pneumonitis. J Allergy Clin Immunol 96:113-121 (1995).
114. Underwood S, Foster M, Raeburn D, Botroms S, Karlsson J-A. Time-course of antigen-induced airway inflammation in the guinea pig and its relationship to airway hyperresponsiveness. Eur Respir J 8:2104-2113 (1995).
115. Blyth DI, Pedrick MS, Savage TJ, Hessel EM, Fattah D. Lung inflammation and epithelial changes in a murine model of atopic asthma. Am J Respir Cell Mol Biol 14:425-438 (1996).
116. Corry DB, Folkesson HG, Warnock ML, Erle DJ, Matthay MA, Wiener-Kronich JP, Locksley RM. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 183:109-117 (1996).
117. Chung KF, Becker AB, Lazarus SC, Frick OL, Nadel JA, Gold WM. Antigen-induced airway hyperresponsiveness and pulmonary inflammation in allergic dogs. J Appl Physiol 58:1347-1353 (1985).
118. Lanes S, Stevenson JS, Codias E, Hernandez A, Sielczak MW, Wanner A, Abraham WM. Indomethacin and FPL-57231 inhibit antigen-induced airway hyperresponsiveness in sheep. J Appl Physiol 61:864-872 (1986).
119. Gundel RH, Gerritsen ME, Gleich GJ, Wegner CD. Repeated antigen inhalation results in a prolonged airway eosinophilia and airway hyperresponsiveness in primates. J Appl Physiol 68:779-786 (1990).
120. Wegner CD, Torcellini CA, Clarke CC, Letts LG, Gundel RH. Effects of single and multiple inhalation of antigen on airway responstveness in monkeys. J Allergy Clin Immunol 87:835-841 (1991).
121. Lukacs NW, Stricter RM, Chensue SW, Kunkel SL. Interleukin- 4-dependent pulmonary eosinophil infiltration in a murine model of asthma. Am J Respir Cell Mol Biol 10:526-532 (1994).
122. Garlisi CG, Falcone A, Kung TT, Stelts D, Pennline KJ, Beavis AJ, Smith SR, Egan RW, Umland RW. T cells are necessary for Th2 cytokine production and eosinophil accumulation in airways of antigen challenged allergic mice. Clin Immunol Immunopathol 75:75-83 (1995).
123. Brusselle G, Kips J, Joos G, Bluethmann H, Pauwels R. Allergen- induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. Am J Respir Cell Mol Biol 12:254-259 (1995).
124. Kung TT, Stelts D, Zurcher JA, Jones H, Umland SP, Kreutner W, Egan RW, Chapman RW. Mast cell modulate allergic pulmonary eosinophilia in mice. Am J Respir Cell Mol Biol 12:404-409 (1995).
125. Blythe S, England D, Esser B, Junk P, Lamanske RF Jr. IgE antibody-mediated inflammation of rat lung: histologic and bronchoalveolar lavage assessment. Am Rev Respir Dis 134:1246-1251 (1986).
126. Eidelman DH, Bellofiore S, Martin JG. Late airway responses to antigen challenge in sensitized inbred rats. Am Rev Respir Dis 137:1033-1037 (1988).
127. Boulet LP, Cartier A, Thomson MC, Roberts RS, Doloviche J, Hargreave FE. Asthma and increases in nonallergic bronchial responsiveness from seasonal pollen exposure. J Allergy Clin Immunol 71:399-406 (1983).
128. Bellofiore S, Martin JG. Antigen challenge of sensitized rats increases airway responsiveness to methacholine. J Appl Physiol 65:1642-1646 (1988).
129. Dunn CJ, Elliott GA, Oosteven JA, Richards IM. Development of a prolonged eosinophil-rich inflammatory leukocyte infiltration in the guinea pig asthmatic response to ovalbumin inhalation. Am Rev Respir Dis 137:541-547 (1988).
130. Savoie C, Plant M, Zwikker M, van Sraden CJ, Boulet L, Chan CC, Rodger IW, Pon DJ. Effect of dexamethasone on allergen- induced high molecular weight glycoconjugate secretion in allergic guinea pigs. Am J Respir Cell Mol Biol 13:133-143 (1995).
131. Andersson P. Antigen-induced bronchial anaphylaxis in actively sensitized guinea pigs. Allergy 35:65-71 (1980).
132. 2 exposure on allergic sensitization in the guinea pig. J Allergy Clin Immunol 82:527-534 (1988).
133. Takano H, Yoshikawa T, Ichinose T, Miyabara Y, Imaoka K, Sagai M. Diesel exhaust particles enhance antigen-induced airway inflammation and local cytokine expression in mice. Am J Respir Crit Care Med 156:36-42 (1997).
134. Wade JF, Newman LS. Diesel asthma. Reactive airways disease following overexposure to locomotive exhaust. J Occup Med 35:149-154 (1993).
135. D'Amaro G, Liccardi G, Cazzola M. Environment and development of respiratory allergy. I: Outdoors. Monaldi Arch Chest Dis 49:406-411 (1994).
136. Jorres R, Nowak D, Magnussen H. The effect of ozone exposure on allergen responsiveness in subjects with asthma or rhinitis. Am J Respir Crit Care Med 153:56-64 (1996).
137. Higgins, MW, Thorn T. Incidence, prevalence, and mortality: intra- and intercountry differences. In: Clinical Epidemiology of Chronic Obstructive Pulmonary Disease (Hensley MJ, Saunders NA, eds). New York:Marcel Dekker, 1989;23-43.
138. Vermeire P. Differential diagnosis in asthma and chronic obstructive pulmonary disease. In: Anticholinergic Therapy in Obstructive Airways Disease (Gross NJ, ed). London:Franklin Scientific, 1993;48-60.
139. Wilmort RW, Tyson SL, Matthe DJ. Cystic fibrosis survival rates: the influences of allergy and Pseudomonas aeruginosa. Am J Dis Child 138:669-671 (1985).
140. Smaldone GC, Foster WM, O'Riordan TG, Messina MS, Perry RJ, Langenback EG. Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest 103:1390-1396 (1993).
141. Kim CS, Kang TC. Comparative measurement of lung deposition of inhalea fine particles in normal subjects and patients with obstructive airway disease. Am J Respir Crit Care Med 155:899-905 (1997).
142. U.S. EPA. Air Quality Criteria for Ozone and Related Photochemical Oxidants. Vol III. EPA/600/p-93/004cF. Washington:U.S. Environmental Protection Agency, 1996;7.17-7.25.
143. Mannino DM, Etzel RA, Parrish G. Pulmonary fibrosis deaths in the United States, 1979-1991. An analysis of multiple-cause mortality data. Am J Respir Crit Care Med 153:1548-1552 (1996).
144. Hepleston AG. Minerals, fibrosis and the lung. Environ Health Perspect 94:149-168 (1991).
145. Cooper JA Jr, Zitnik RJ, Matthay RA. Mechanism of drug- induced pulmonary disease. Annu Rev Med 39:395-404 (1988).
146. Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin- induced lung damage. Arch Toxicol 65:81-94 (1991).
147. Sweeney TD, Brain JD, Tryka AF, Godleski JJ. Retention of inhaled particles in hamsters with pulmonary fibrosis. Am Rev Respir Dis 128:138-143 (1983).
148. Raghow R, Lurie S, Seyer JM, Kang AH. Profile of steady state levels of messenger RNAs coding for type I procollagen, elastin, and fibronectin in hamster lungs undergoing bleomycin induced interstitial pulmonary fibrosis. J Clin Invest 76:1733-1739 (1985).
149. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or over express the murine plasmalogen activator inhibitor-I gene. J Clin Invest 97:232-237 (1996).
150. Haston CK, Amos CI, King TM, Travis EL. Inheritance of susceptibility to bleomycin-induced pulmonary fibrosis in the mouse. Cancer Res 56:2596-2601 (1996).
151. Lazenby AJ, Crouch EC, McDonald JA, Kuhn III C. Remodeling of the lung in bleomycin-induced pulmonary fibrosis in the rats. An immunohistochemical study of laminin, type IV collagen, and fibronectin. Am Rev Respir Dis 142:206-214 (1990).
152. Hernnas J, Nettelbladt O, Bjermer L, Sarnstrand B, Malmstrom A, Hallgren R. Alveolar accumulation of fibronectin and hyaluronan precedes bleomycin-induced pulmonary fibrosis in rats. Eur Respir J 5:404-410 (1992).
153. Khalil N, O'Connor RN, Flanders KC, Shing W, Whitman CI. Regulation of type II alveolar epithelial cell proliferation by TGF- β during bleomycin-induced lung injury in rats. Am J Physiol 267 (Lung Cell Mol Physiol 11):L498-L507 (1994).
154. Shaw RJ, Benedict SH, Clark RAF, King Jr TE. Pathogenesis of pulmonary fibrosis in interstitial lung disease. Alveolar macrophage PDGF(B) gene activation and up-regulation by interferon gamma. Am Rev Respir Dis 143:167-173 (1991).
155. Lehmann JR, Costa DL, Slatkin DL. Diffuse interstitial fibrosis in the rat: an approach using bleomycin in combination with oxygen [Abstract]. Toxicologist 4:63 (1984).
156. Bolm-Muilwijk MC, Vriesendorp R, Veninga TS, Hofstra W, Sleyfer DT, Wieringa RA, Konings AW. Pulmonary toxicity after treatment with bleomycin alone or in combination with hyperoxia. Studies in the rat. Br J Anaesth 60:91-97 (1988).
157. Tryka AF, Sweeney TD, Brain JD, Godleski JJ. Short-term regional clearance of an inhaled submicrometric aerosol in pulmonary fibrosis. Am Rev Respir Dis 132:606-611 (1985).
158. Crouch E, Pathobiology of pulmonary fibrosis. Am J Physiol 259 (Lung Cell Mol Physiol 3):L159-L184 (1990).
159. 2. Health Phys 60:353-363 (1991).
160. Adamson IYR, Prieditis H. Response of mouse lung to carbon deposition during injury and repair. Environ Health Perspect 103(1):72-76 (1995).
161. Hippeli S, Elstner EF. Biological and biochemical effects of air pollutants: synergistic effects of sulfite. Biochem Soc Symp 61:153-161 (1995).
162. O'Reilly T. Relevance of animal models for chronic bacterial airway infections in humans. Am J Respir Crit Care Med 151:2101-2108 (1995).
163. Maciver I, Silverman SH, Brown MRW, O'Reilly T. Rat model of chronic lung infections caused by non-typable Haemophilus influence. J Med Microbiol 35:139-147 (1991).
164. Chen W, Havell EA, Harmsen AG. Importance of endogenous tumor necrosis factor alpha and gamma interferon in host resistance against Pneumocystis carinii infection. Infect Immunol 60:1279-1284 (1992).
165. Waxman AB, Goldie SJ, Brett-Smith H, Matthay RA. Cytomegalovirus as a primary pulmonary pathogen in AIDS. Chest 111:128-134 (1997).
166. Groeneveld K, van Alphen L, Eijik PP, Visschers G, Jansen HM, Zanen HC. Endogenous and exogenous reinfection by Haemophilus influenzae in patients with chronic obstructive pulmonary disease: the effect of antibiotic treatment on persistence. J Infect Dis 161:512-517 (1990).
167. Jansen HM, Sachs PE, Alphen LV. Predisposing conditions of bacterial infections in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 151:2073-2080 (1995).
168. Torres A, Dorca J, Zalacain R, Bello S, El-Ebiary M, Molinos L, Arevalo M, Blanquer J, Celis R, Iriberri M et al. Community- acquired pneumonia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 154:1456-1461 (1996).
169. Price JF. Acute and long-term effects of viral bronchiolitis in infancy. Lung 168(Suppl):414-421 (1990).
170. Lowenberg A, Orie NGM, Sluiter HJ, de Vries K. Bronchial hyperreactivity and bronchial obstruction in respiratory viral inrection. Respiration 49:1-9 (1986).
171. Glezen WP. Reactive airway disorders in children. Role of respiratory virus infections. Clin Chest Med 5:635-643 (1984).
172. Mok JYQ, Simpson H. Outcome of acute bronchitis, bronchiolitis and pneumonia in infancy. Arch Dis Child 59:306-309 (1984).
173. + T cells to a "TH2-like" phenorype: a link between viral infections and bronchial asthma. Ann NY Acad Sci 796:97-103 (1996).
174. Holtzman MJ, Sampath D, Castro M, Look DC, Jayaraman S. The one-two of T helper cells: does interferon-γ knock out the Th2 hypothesis for asthma? Am J Respir Cell Mol Biol 14:316-318 (1996).
175. Roman M, Calhoun WJ, Hinton KL, Avendano LF, Simon V, Escobar AM, Gaggero A, Diaz PV. Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. Am J Respir Grit Care Med 156:190-195 (1997).
176. Castleman WL, Sorkness RL, Lamanske RF, Grasee G, Suyemoto MM. Neonatal viral bronchiolitis and pneumonia induces bronchiolar hyperplasia and alveolar dysplasia in rats. Lab Invest 59:387-396 (1988).
177. Castleman WL, Sorkness RL, Lemanske RF Jr, McAllister PK. Viral bronchiolitis during early life induces increased numbers of bronchiolar mast cells and airway hyperresponsiveness. Am J Pathol 137:821-831 (1990).
178. Sorkness R, Lemanske RF Jr, Castleman WL. Persistent airway hyperresponsiveness after neonatal viral bronchiolitis in rats. J Appl Physiol 70:375-383 (1991).
179. Pullan CR, Hey EN. Wheezing, asthma, and pulmonary disfunction 10 years after infection with respiratory syncytial virus in infancy. Br Med J 284:1665-1669 (1982).
180. Hall CB, Hall WJ, Gala CL, MaGill FB, Leddy JP. Long-term prospective study in children after respiratory syncytial virus infection. J Pediatr 105:358-364 (1984).
181. Sly PD, Hibbert ME. Childhood asthma following hospitalization with acute viral bronchiolitis in infancy. Pediatr Pulmonol 7:153-158 (1989).
182. Taylor G, Stott EJ, Hughes M, Collins AP. Respiratory syncytial virus infection in mice. Infect Immunol 43:649-655 (1984).
183. Hegele RG, Robinson PJ, Gonzalez S, Hogg JC. Production of acute bronchiolitis in guinea-pigs by human respiratory syncytial virus. Eur Respir J 6:1324-1331 (1993).
184. Lebrec H, Burleson GR. Influenza virus host resistance models in mice and rats: utilization for immune function assessment and immunotoxicology. Toxicology 91:179-188 (1994).
185. Hegele RG, Hayashi S, Hogg JC, Pare PD. Mechanisms of airway narrowing and hyperresponsiveness in viral respiratory tract infections. Am J Respir Grit Care Med 151:1659-1665 (1995).
186. Dye JA, Morgan KT, Neldon DL, Tepper JS, Burleson GR, Costa DL. Characterization of upper respiratory disease in rats following neonatal inoculation with a rat-adapted influenza virus. Vet Pathol 33:43-54 (1996).
187. Graham BS, Perkins MD, Wright PF, Karzon DT. Primary respiratory syncytial virus infection in mice. J Med Virol 26:153-162 (1988).
188. Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 93:771-792 (1978).
189. Selgrade MJK, Hung JW, Starnes DM, Stead AG, Menache MG, Stevens MA. Evaluation of effects of ozone exposure on influenza infection in mice using indicators of susceptibility. Fundam Appl Toxicol 11:169-180 (1988).
190. Jakab GJ, Hmieleski RR. Reduction of influenza virus pathogenesis by exposure to 0.5 ppm ozone. J Toxicol Environ Health 23:455-472 (1988).
191. Jakab GJ, Bassett JP. Influenza virus infection, ozone exposure, and fibrogenesis. Am Rev Respir Dis 141:1307-1315 (1990).
192. Ehrlich JP, Burleson GR. Enhanced and prolonged pulmonary influenza virus infection following phosgene inhalation. J Toxicol Environ Health 34:259-273 (1991).
193. Gilmour IM, Daniels MJ, Winsett D, Costa DL, Seigrade MJK. Oil fly ash exposure enhances airway responsiveness and pulmonary inflammation to influenza virus infection in rats. Toxicologist 36:7 (1997).
194. Gilmour MI, Koren HS. Interaction of inhaled particles with the immune system. In: Particle-Lung Interactions (Gehr P, Heyder J, eds). New York:Marcel Dekker, in press.
195. Tepper JS, Winsett DW, Dye JA, Burleson GR, Costa DL. Can environmental pollutants exacerbate virus-induced airway hyperres ponsiveness [Abstract]. Toxicologist 13:A55 (1993).
196. + cells in resistance to Pneumocystis carinii pneumonia in mice. J Exp Med 172:937-945 (1990).
197. Walzer PD, Powell RD, Yoneda K. Experimental Pneumocystis carinii pneumonia in different strains of cortisonized mice. Infect Immunol 24:939-947 (1979).
198. Chen W, Havell EA, Gigliotti F, Harmsen AG. Interleukin-6 production in a murine model of Pneumocystis carinii pneumonia: relation to resistance and inflammatory response. Infect Immunol 61:97-102 (1993).
199. 3 exposure: differences in disease susceptibility and neutrophil recruitment. Toxicol Appl Pharmacol 123:211-218 (1993).
200. Beaulac C, Clement MS, Hawari J, Lagace J. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic infection. Antimicrob Agents Chemorher 40:665-669 (1996).
201. Overcash RG, Lindsey JR, Cassel GH, Baker HJ. Enhancement of natural and experimental respiratory mycoplasmosis in rats by hexamethylphospnoramide. Am J Pathol 82:171-190 (1976).
202. Boyd RL, Ramphal R, Rice R, Mangos JA. Chronic colonization of rat airways with Pseudomonas aeruginosa. Infect Immunol 39:1403-1410 (1983).
203. Coffin DL, Gardner DE. Interaction of biological agents and chemical air pollutants. Ann Occup Hyg 15:219-234 (1972).
204. Ehrlich R, FindlayJC, Fenters JD, Gardner DE. Health effects of short-term inhalation of nitrogen dioxide and ozone mixtures. Environ Res 4:223-231 (1977).
205. Sherwood RL, Tarkingron B, Lippert WE, Goldsrein E. Effect of ferrous sulphate aerosols and nitrogen dioxide aerosols in murine pulmonary defense. Arch Environ Health 36:130-135 (1981).
206. Gardner DE. Effects of gases and airborne particles on lung infections. In: Air Pollution: Physiological Effects (McGrath JJ, Barnes EB, eds). New York:Academic Press, 1982;47-79.
207. Selgrade MJK, Starnes DM, Illing JW, Daniels MJ, Graham JA. Effects of phosgene exposure on bacterial, viral, and neoplastic lung disease susceptibility in mice. Inhal Toxicol 1:243-259 (1989).
208. Hatch GE, Boykin E, Graham JA, Lewtas J, Pott F, Loud K, Mumford JL. Inhalable particles and pulmonary host defense: in vivo and in vitro effects of ambient air and combustion particles. Environ Res 36:67-80 (1985).
209. Scharf SM, Cassady SS, eds. Heart-Lung Interactions in Health and Disease. New York:Marcel Dekker, 1989.
210. Mukaddam-Daher S, Tremblay J, Fujio N, Koch C, Jankowski M, Quileen EW Jr, Gutkowska J. Alterations of lung atrial natriuretic peptide receptors in genetic cardiomyopathy. Am J Physiol 271 (Lung Cell Mol Physiol 15):L38-L4 5 (1996).
211. Fessier HE. Heart-lung interactions: applications in the critically ill. Eur Respir J 10:226-237 (1997).
212. Fagard R, Lijnen P, Staessen J, Verschuere J, Amery A. The pulmonary circulation in essential systemic hypertension. Am J Cardiol 61:1061-1065 (1988).
213. Feidstein CA, Sabaros RP, Cohen A, lermoli R. Dynamics of the pulmonary circulation in systemic hypertension. Am J Hypertens 1:113S-116S (1988).
214. Aharinejad S, Schraufnagel DE, Bock P, MacKay CA, Larson EK, Miksovsky A, Marks SC Jr. Spontaneously hypertensive rats develop pulmonary hypertension and hypertrophy of pulmonary venous sphincters. Am J Pathol 148:281-290 (1996).
215. Robinovitch M. Pulmonary hypertension. In: Heart Disease in Infants, Children, and Adolescents (Moss AJ, Adams FM, Emmanoluilides GC, eds). Baltimore:Williams & Wilkins, 1989;856-885.
216. Hultgren HN, Grover RF. Circulating adaptation to high altitude. Ann Rev Med 19:119-152 (1968).
217. Robinovitch M, Bothwell T, Hayakawa BN, Williums WG, Trusler GA, Rowe RD, Olley PM, Cutz E. Pulmonary arterial endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension: a correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest 55:632-653 (1986).
218. Robinovitch M. Investigational approaches ro pulmonary hypertension. Toxicol Pathol 19:458-469 (1991).
219. Wilson DW, Segall HJ, Pan LC, Lame MW, Estep JE, Morrin D. Mechanisms and pathology of monocroraline roxicity. Crit Rev Toxicol 22:307-325 (1992).
220. Huxtable RJ. Hepatic nonaltruism and pulmonary toxicity of pyrrolizidine alkaloids. In: Metabolic Activation and Toxicity of Chemical Agents to Lung Tissue and Cells (Gram TE, ed). Oxford, United Kingdom:Pergamon Press, 1993;213-237.
221. Durmowicz AG, Parks WC, Hyde DM, Mecham RP, Stenmark KR. Persistence, re-expression, and induction of pulmonary arterial fibronectin, tropoelastin, and type I procollagen mRNA expression in neonatal hypoxic pulmonary hypertension. Am J Pathol 145:1411-1420 (1994).
222. Hill NS, Klinger JR, Warburton RR, Pietras L, Wrenn DS. Brain natriuretic peptide: possible role in the modulation of hypoxic pulmonary hypertension. Am J Physiol 266 (Lung Cell Mol Physiol 10):L308-L315 (1994).
223. Li H, Chen S-J, Chen Y-F, Meng QC, Durand J, Oparil S, Elton TS. Enhanced endothelin-I and endothelin receptor gene expression in chronic hypoxia. J Appl Physiol 77:1451-1459 (1994).
224. Tuder RM, Flook BE, Voelkel NF. Increased gene expression of VEGF and VEGF receptors KDR/Flk and Fit in lungs exposed to acute or chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 95:1798-1807 (1995).
225. Meyrick B. Structure function correlates in the pulmonary vasculature during acute lung injury and chronic pulmonary hypertension. Toxicol Pathol 19:447-457 (1991).
226. Roth RA, Ganey PE. Platelets and puzzles of pulmonary pyrrolizidine poisoning. Toxicol Appl Pharmacol 93:463-471 (1988).
227. Schultze AE, Roth RA. Fibrinolytic activity in blood and lungs of rats treated with monocrotaline pyrrole. Toxicol Appl Pharmacol 121:129-137 (1993).
228. Zhu L, Wigle D, Hinek A, Kobayashi J, Ye C Zuker M, Dodo H, Keeley FW, Rabinovitch M. The endogenous vascular elastase that governs development and progression of monocrotalineinduced pulmonary hypertension in rats is a novel enzyme related to the serine proteinase adipsin. J Clin Invest 94:1163-1171 (1994).
229. Rosenberg HC, Robinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol 255:H1484-H1491 (1988).
230. Reindel JF, Ganey PE, Wagner JG, Slocombe RF, Roth RA. Development of morphologic, hemodynamic, and biochemical changes in lungs of rats given monocrotaline pyrrole. Toxicol Appl Pharmacol 106:179-200 (1990).
231. Schultze AE, Wagner JG, White SM, Roth RA. Early indicators of monocroraline pyrrole-induced lung injury in rats. Toxicol Appl Pharmacol 109:41-50 (1991).
232. Lai YL, Thacker AA, Dianna JN. Hypoxemia and elevated tachykinins in rat monocrotaline pneumoroxicity. Lung 174:195-203 (1996).
233. Hill NS, Jederlinic P, Gagnon J. Supplemental oxygen reduces right ventricular hypertrophy in monocrotaline-injected rats. J Appl Physiol 66:1642-1648 (1989).
234. Schultze AE, Wagner JG, Roth RA. An evaluation of procoagulant activity in the peripheral blood of rats treated with monocrotaline pyrrole. Toxicol Appl Pharmacol 109:421-431 (1991).
235. Maruyama K, Ye C, Woo M, Venkatacharya H, Lines LD, Silver MM, Rabinovitch M. Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity. Am J Physiol 261 (Heart Circ Physiol 30):H1716-H1726 (1991).
236. McKenzie JC, Kelly KB, Merisko-Liversidge EM, Kennedy J, Klein RM. Developmental pattern of ventricular aerial natriuretic pepride (ANP) expression in chronically hypoxic rats as an indicator of the hypertrophic process. J Mol Cell Cardiol 26:753-767 (1994).
237. Resta TC, Russ RD, Doyle MP, Martinez JM, Walker BR. Cardiovascular responses to hemorrhage during acute and chronic hypoxia. Am J Physiol 267 (Regulatory Interactive Comp Physiol 36):R619-R627 (1994).
238. Vaziri ND, Wang ZQ. Sustained systemic arterial hypertension induced by extended hypobaric hypoxia. Kidney Int 49:1457-1463 (1996).
239. Vyas-Somani AC, Aziz SM, Arcot SA, Gillespie MN, Olson JW, Lipke DW. Temporal alterations in basemenr membrane components in the pulmonary vasculature of chronically hypoxic rat: impact of hypoxia and recovery. Am J Med Sci 312:54-67 (1996).
240. Yamaguchi K, Kami Y, Asano K, Takasugi T, Tanaka T, Yasuoka M, Hosoda Y. Temporal alterations of endothelial-vasodilator functions in lung injury induced by monocrotaline. Respir Physiol 107:47-58 (1997).
241. Xue C, Rengasamy A, Le Cras TD, Koberna PA, Dailey GC, Johns R. Distribution of NOS in normoxic vs. hypoxic rat lung: upregulation of NOS by chronic hypoxia. Am J Physiol 267 (Lung Cell Mol Physiol 11):L667-L678 (1994).
242. Zhao L, Winter RJD, Krausz T, Hughes JMB. Effects of continuous infusion of atrial natriuretic peptide on the pulmonary hypertension induced by chronic hypoxia in rats. Clin Sci 81:397-385 (1991).
243. Shreeniwas R, Koga S, Karakurum M, Pinsky D, Kaiser E, Brett J, Wolitzky BA, Norton C, Plocinski J, Benjamin W et al. Hypoxia-mediated induction of endothelial cell interleukin-1α. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 90:2333-2339 (1992).
244. Yan SF, Tritto I, Pinsky D, Liao H, Huang J, Fuller G, Brett J, May L, Stern D. Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor- IL-6. J Biol Chem 270:11463-11471 (1995).
245. Wiederman HP, Matthay RA. The management of acute and chronic cor pulmonale. In: Heart-Lung Interactions in Health and Disease (Scharf SM, Cassidy SS, eds). New York:Marcel Dekker, 1989;915-981.
246. NCHS. Health United States 1992 and Healthy People 2000 Review. DHHS Publ No (PHS) 93-1232. Hyattsville, MD:National Center for Health Statistics, 1992;48-51.
247. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 349:1269-1276 (1997).
248. Ganten D, de Jong W. Experimental and genetic models of hypertension. In: Handbook of Hypertension Vol 16. (Birkenhager WH, Reid JT, series eds). New York:Elsevier, 1994.
249. Elsner D, Riegger GAJ. Characteristics and clinical relevance of animal models of heart failure, Curr Opinion Cardiol 10:253-259 (1995).
250. Eisner D, Riegger GAJ. Animal models of heart failure. Curr Opinion Cardiol 6:334-340 (1991).
251. Rubattu S, Struk B, Kreuts R, Volpe M, Lindpaintner K. Animal models of genetic hypertension: what can we learn for human hypertension? Clin Exp Pharmacol Physiol Suppl 2:S386-S393 (1995).
252. Johns C, Gavras I, Handy DE, Salomao A, Gavras H. Models of experimental hypertension in mice. Hypertension 28:1064-1069 (1996).
253. Bing OH, Brooks WW, Robinson KG, Slawsky MT, Hayes JA, Litwin SE, Sen S, Conrad CH. The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol 27:383-396 (1995).
254. Korner PI. Cardiovascular hypertrophy and hypertension: causes and consequences. Blood Pressure 4(Suppl 2):6-16 (1995).
255. Kurokawa K. Role of the kidney in the genesis of hypertension: aberrant renal responses to excess salt intake. Clin Exp Pharmacol Physiol Suppl 2:S417-S422 (1995).
256. Yamori Y, Murakami S, Nara Y, Ikeda K. Stroke-prone SHR and arteriolipidosis-prone SHR as models for atherosclerosis: their mechanisms and application for nutritional and pharmacological studies. Clin Exp Pharmacol Physiol Suppl 1:S244-S245 (1995).
257. Feng Q-P, Bergdahl A, Lu X-R, Sun X-Y, Edvinsson L, Hedner T. Vascular alpha-2 adrenoceptor function is decreased in rats with congestive heart failure. Cardiovasc Res 31:577-584 (1996).
258. Gerdes AM, Onodera T, Wang X, McCune SA. Myocyte remodeling during the progression to failure in rats with hypertension. Hypertension 28:609-614 (1996).
259. Cowley AW Jr, Roman RJ. The role of the kidney in hypertension. J Am Med Assoc 275:1581-1589 (1996).
260. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. J Am Med Assoc 275:1557-1563 (1996).
261. Committee on the care and use of spontaneously hypertensive (SHR) rats. Spontaneously hypertensive (SHR) rats: guidelines for breeding care and use. Inst Lab Animal Res News XIX:G2-G20 (1976).
262. Sassard J, Benzoni D. Prostaglandins and sodium handling in Lyon hypertensive rats. Clin Exp Pharmacol Physiol Suppl 2:S423-S425 (1995).
263. Lal KJ, Dakshinamurti K, Thliveris J. The effect of vitamin B6 on the systolic blood pressure of rats in various animal models of hypertension.J Hypertension 14:355-363 (1996).
264. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OHL. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation 91:161-170 (1995).
265. Mamuya W, Chobanian A, Brecher P. Age-related changes in fibronectin expression in spontaneously hypertensive, Wistar- Kyoto, and Wistar rat hearts. Circ Res 71:1341-1350 (1992).
266. Campese VM, Tawadrous M, Bigazzi R, Blanchi S, Mann AS, Oparil S, Raij L. Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension. Hypertension 28:335-340 (1996).
267. Rapp JP. The genetics of hypertension in Dahl rats. In: Experimental and Generic Models of Hypertension. Vol 16 (Ganten D, de Jong W, eds). Handbook of Hypertension (Birkenhager WH, Reid JT, series eds). New York:Elsevier, 1994;186-201.
268. Ernsberger P, Koletsky RJ, Collins LA, Bedol D. Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agents. Cardiovasc Drug Ther 10:275-282 (1996).
269. Ideishi M, Miura S-I, Sakai T, Maeda H, Kinoshita A, Sasaguri M, Jimi S, Arakawa K. Comparative effects of an angiotensinconverting enzyme inhibitor and an angiotensin II antagonist in Dahl rats. Blood Pressure 3(Suppl 5):99-104 (1994).
270. Yamazaki K, Katoh H, Yamamoto N, Kurihara K, lobe H, Sonoda J, Kuwabara A, Wakabayashi T. Characterization of new inbred strains of Dahl-Iwai salt-sensitive and salt-resistant rats. Lab Anim Sci 44:462-467 (1994).
271. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harboring the mouse Ren-2 gene. Nature 344:541-544 (1990).
272. Bachmann S, Peters J, Engler E, Ganten D, Mullins J. Transgenic rats carrying the mouse renin gene: morphological characterization of low renin model. Kidney Int 41:24-36 (1992).
273. Ganten D, Wagner J, Zeh K, Bader M, Michel JB, Paul M, Zimmermann F, Ruf P, Hilgenfeldr U, Ganten U et al. Species- specificity of renin kinetics in transgenic rats harboring the human renin and angiotensiogen genes. Proc Nad Acad Sci USA 89:7806-7810 (1992).
274. Lo M, Medeiros IA, Mullins JJ, Ganten D, Barres C, Cerutti C, Vincent M, Sassard J. High blood pressure maintenance in transgenic mRen-2 vs Lyon genetically hypertensive rats. Am J Physiol 265 (Regul Integ Comp Physiol 34):R180-R186 (1993).
275. Villarreal FJ, MacKenna DA, Omens JH, Dillmann WH. Myocardial remodeling in hypertensive Ren-2 transgenic rats. Hypertension 25:98-104 (1995).
276. Wagner J, Thiele F, Ganten D. The renin-angiotensin system in transgenic rats. Pediatr Nephrol 10:108-112 (1996).
277. Bohm M, Moll M, Schmid B, Paul M, Ganten D, Castellano M, Erdmann E. β-Adrenergic neuroeffector mechanisms in cardiac hypertrophy of renin transgenic rats. Hypertension 24:653-662 (1994).
278. Russell JC, Koeslag DG, Amy RM, Dolphin PJ. Myocardial disease and catecholamine metabolism in JCR:LA-corpulent rat. Exp Mol Parhol 54:31-40 (1991).
279. Okamoto K, Yamamoto K, Morita N, Ohtay, Chikugo T, Higashizawa T, Suzuki T. Establishment and use of the M strain of stroke-prone spontaneously hypertensive rat. J Hypertension 4(Suppl III) :S21-S24 (1986).
280. Yamori Y. Selection of arteriolipidosis-prone rats (ALR). Jpn Heart J 18:602-603 (1977).
281. Hansen CT. Two new congenic strains For nutrition and obesity research. Fed Proc 42:537 (1983).
282. Greenhouse DD, Michaelis OE, Peterson RG. The development of fatty and corpulent rat strains. In: New Models of Genetically Obese Rats for Studies in Diabetes, Heart Disease, and Complications of Diabetes (Hansen CT, Michaelis OE, eds). Bethesda, MD:National Institutes of Health, 1988;3-6.
283. Bray GA. The Zucker-fatty rat: a review. Fed Proc 36:148-153 (1977).
284. Yagil C, Ben-Ishay D, Yagil Y. Disparate expression of the AVP gene in Sabra hypertension-prone and hypertension-resistant rats. Am J Physiol 271 (Renal Fluid Electrolyte Physiol 40):F806-F813 (1996).
285. Bishop SP. Animal models. In: Congestive Heart Failure. Current Research and Clinical Applications (Braunwald E, Mock MB, Watson JT, eds). New York:Grune & Stratum, 1982;125-149.
286. Arnal J-F, Philippe M, Laboulandine I, Michel J-B. Effect of perindopril in rat cardiac volume overload. Am Heart J 126:776-782 (1993).
287. Arai M, Suzuki T, Nagai R. Sarcoplasmic reticulum genes are upregulated in mild cardiac hypertrophy but downregulated in severe cardiac hypertrophy induced by pressure overload. J Mol Cell Cardiol 28:1583-1590 (1996).
288. Itani MM, Talerico MG, Pino PA, Burke-Wolin T. Early regulatory changes in rat pulmonary artery of renin-dependent systemic hypertension models. Am J Respir Cell Mol Biol 15:467-472 (1996).
289. Wahlander H, Haraldsson B, Friberg P. Myocardial capillary diffusion capacity in rat hearts with cardiac hypertrophy due to pressure and volume overload. Am J Physiol 265 (Heart Circ Physiol 34):H61-H68 (1993).
290. Duan J, Jaramillo J, Jung GL, McLeod AL, Fernandes BH. A novel renal hypertensive guinea pig model for comparing different inhibitors of the renin-angiotensin system. J Pharmacol Toxicol Meth 35:83-89 (1996).
291. Seyle H, Bajusz E, Grasso S, Mendell P. Simple techniques for the surgical occlusion of coronary vessels in the rat. Angiology 11:398-407 (1960).
292. Chasteney EA, Liang C-S, Hood WB Jr. β-Adrenoceptor and adenylate cyclase function in the infarct model of rat heart failure. Proc Soc Exp Biol Med 200:90-94 (1992).
293. +-ATPase activity in congestive heart failure due to myocardial infarction. Am J Physiol 262 (Cell Physiol 31):C664-C671 (1992).
294. Medvedev OS, Goroderskaya EA. Systemic and regional hemodynamic effects of perindopril in experimental heart failure. Am Heart J 126:764-769 (1993).
295. Pelouch V, Dixon IMC, Sethi R, Dhalla NS. Alteration of collagenous protein profile in congestive heart failure secondary to myocardial infarction. Mol Cell Biol 129:121-131 (1994).
296. Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol 148:291-300 (1996).
297. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest 40:208-215 (1983).
298. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I: Smooth muscle growth in the absence of endothelium. Lab Invest 49:327-333 (1983).
299. Fraser-Smith EB, Rosete JD, Schatzman RC. Suppression by mycophenolate mofetil of the neointimal thickening caused by vascular injury in a rat arterial stenosis mode). J Pharmacol Exp Ther 275:1204-1208 (1995).
300. Woodruff JF. Viral myocarditis. Am J Pathol 101:427-478 (1980).
301. Fenoglio JJ Jr, Ursell PC, Kellogg CF, Drusin RE, Weiss MB. Diagnosis and classification of myocarditis by endocardial biopsy. N Engl J Med 308:12-18 (1983).
302. Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 57:250-262 (1990).
303. Koyama S, Kodama M, Izumi T, Shibata A. Experimental rat model representing both acute and chronic heart failure related to autoimmune myocarditis. Cardiovasc Drug Ther 9:701-707 (1995).
304. Rosenthal DS, Handin, RI, Braunwald E. Hematologic-oncologic disorders and heart disease. In: Heart Disease: A Textbook of Cardiovascular Medicine (Braunwald E, ed). Philadelphia:WB Saunders, 1984;1690-1692.
305. Ambler GR, Johnston BM, Maxwell L, Gavin JB, Gluckman PD. Improvement of doxorubicin induced cardiomyopathy in rats treated with insulin-like growth factor 1. Cardiovasc Res 27:1368-1373 (1993).
306. Wakasugi S, Fischman AJ, Babich JW, Callahan RJ, Elmaleh DR, Wilkinson R, Strauss HW. Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy. J Nucl Med 34:1529-1535 (1993).
307. Mettler FP, Young DM, Ward JM. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res 37:2705-2713 (1977).
308. Cottin Y, Ribuot C, Maupoil V, Godin D, Arnould L, Brunotte F, Rochette L. Early incidence of adriamycin treatment on cardiac parameters in the rat. Can J Pharmacol Physiol 72:140-145 (1994).
309. Monti E, Prosperi E, Supino R, Borriroli G. Free radical-dependent DNA lesions are involved in the delayed cardiotoxicity induced by adriamycin in the rat. Anticancer Res 15:193-198 (1995).
310. Venkatesan N, Ramesh CV, Jayakumar R, Chandrakasan G. Angiotensin I converting enzyme activity in adriamycin induced nephrosis in rats. Toxicology 85:137-148 (1993).
311. Yokoto N, Yamamoto Y, Iemura F, Kita T, Kangawa K, Minamino N, Eto T. Increased plasma levels and brain natriuretic peptide in experimental nephrosis. Nephron 65:454-459 (1993).
312. Bajusz E. Hereditary cardiomyopathy: a new disease model. Am Heart J 77:686-696 (1969).
313. Bajusz E, Baker JR, Nixon CW, Homburger F. Spontaneous hereditary myocardial degeneration and congestive heart failure in a strain of Syrian hamsters. Ann NY Acad Sci 156:105-129 (1969).
314. Capasso JM, Olivetti G, Anversa P. Mechanical and electrical properties of cardiomyopathic hearts of Syrian hamsters. Am J Physiol 257 (Heart Circ Physiol 26):H1836-H1842 (1989).
315. Factor, SM, Minase T, Cho S, Dominitz R, Sonnenblick EH. Microvascular spasm in the cardiomyopathic Syrian hamster: a preventable cause of focal myocardial necrosis. Circulation 66:342-354 (1982).